Baupost Group Increases Translate Bio Stake | Value Investing News

Baupost Group Increases Translate Bio Stake

  • Per the filing, Baupost now owns 24.06% of the company with over 12.27 million shares as of August 31st.
  • The company is developing MRT5005, which is in Phase I/II clinical trial for the treatment of cystic fibrosis; and MRT5201 to treat ornithine transcarbamylase deficiency.
  • It has a collaboration and license agreement with Sanofi Pasteur Inc. to develop mRNA vaccines for up to five infectious disease pathogens.
Rating: 
No votes yet
Article Link: 
Shared Count: 
0
Value Score: 
-5
Category: